News and events Discover how our research has made the news. NewsUS FDA approval for Vyvgart (efgartigimod) for the treatment of generalized myasthenia gravis (gMG) in adults.The recently approved Nirsevimab is based on Ward Ober lab’s half-life extended antibodies. EventsCheck back here for upcoming events.
